US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase price is $55m in cash to be paid upon consummation of the sale with up ...

PARIS, France I July 28, 2025 I Genethon, a worldwide pioneer and leader in research and development in gene therapy for rare genetic diseases, has received ...

Indication SEPHIENCE is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE ...

LONDON, UK I July 28, 2025 I GSK plc (LSE/NYSE: GSK) today announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to ...

COPENHAGEN, Denmark I July 28, 2025 I Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has approved ...

BOLOGNA, Italy I July 28, 2025 I Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT ...

NEW ORLEANS, LA, USA I July 28, 2025 I South Rampart Pharma, Inc., a clinical-stage biopharmaceutical company focused on innovative non-opioid pain therapies, ...

Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements.

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative ...

HONG KONG, China I July 28, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration ...

JIANGSU, China I July 27, 2025 I Hengrui Pharma (600276.SH; 01276.HK) today announced it has entered into agreements with GSK plc (LSE/NYSE: GSK) to develop ...

DAEJEON, South Korea I July 28, 2025 I Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal ...